Protein Arginine Methyltransferase 5 (PRMT5) Inhibitors in Oncology Clinical Trials: A review

Protein arginine methyltransferase 5 (PRMT5) inhibitors are a new class of antineoplastic agents showing promising preliminary clinical efficacy. Targeting an enzyme involved in a wide array of cellular and transcriptional pro-oncogenic processes, this class offers multifaceted tumor-suppressive eff...

Descripción completa

Detalles Bibliográficos
Autores principales: Feustel, Kavanya, Falchook, Gerald S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Innovative Healthcare Institute 2022
Materias:
Review Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9390703/
https://www.ncbi.nlm.nih.gov/pubmed/36034581
http://dx.doi.org/10.36401/JIPO-22-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9390703/
https://www.ncbi.nlm.nih.gov/pubmed/36034581
http://dx.doi.org/10.36401/JIPO-22-1

Ejemplares similares